Welcome to SuperLan Chemical Co.,Ltd.
Home > Products > Metabolism > IDO > NLG919

NLG919

(CAS No:1402836-58-1)
NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1.
CAS No:1402836-58-1
Molecular Weight(MW):282.38
Purity:98%+
Specification:500mg;1g;5g;10g;50g;100g
Price and large packaging, please e-mail consultation:info@SuperLan-chem.com
QC Documents
 COA  MSDS  HPLC  NMR
ChemicalInfomation
CAS No: 1402836-58-1
Molecular formula(MF) C18H22N2O
Molecular Weight(MW): 282.38
Alias
Solubility
In vitro Ethanol 30 mg/mL (106.23 mM)
DMSO 15 mg/mL warmed (53.11 mM)
Water <1 mg/mL
In vivo
Biological Activity
Description NLG919 is a potent IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki/EC50 of 7 nM/75 nM in cell-free assays. Phase 1.
Targets
IDO [1]
(Cell-free assay)
75 nM(EC50)
In vitro

NLG919 potently blocks IDO-induced T-cell suppression and restored robust T-cell responses with ED50 of 80 nM. Similarly, using IDO-expressing mouse DCs from tumor-draining lymph nodes, NLG919 abrogated IDO-induced suppression of antigen-specific T cells (OT-I) in vitro, with ED50 of 120 nM. [1]

In vivo In mice, a single oral administration of NLG919 reduces the concentration of plasma and tissue Kyn by ~ 50%. In mice bearing B16F10 tumors, NLG919 markedly enhances the antitumor responses of naive, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA.[1]